Ori Gutwerg sold $323k of ANIP
SVP, GENERICS at ANI PHARMACEUTICALS INC. 5,384 shares at an average of $60.00, traded Mar 5, 2025, filed Mar 7, 2025.
Score components
- +15RoleOfficer
- +14Trade size$323k at market
- 0Share of holdings soldSold 5.4% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001846478-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2025 | MOption exercise Common Stock | +300 | $31.49 | $9,447 | 99,476 | Mar 7, 2025 |
| Mar 5, 2025 | SOpen-market sale Common Stock | -300 | $60.03 | $18k | 99,176 | Mar 7, 2025 |
| Mar 5, 2025 | SOpen-market sale Common Stock | -5,084 | $60.00 | $305k | 94,092 | Mar 7, 2025 |
| Mar 5, 2025 | MOption exercise Stock Option (right to buy)derivative | -300 | $31.49 | $9,447 | 13,204 | Mar 7, 2025 |
Related signals
Other insiders at ANI PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $208k 2,850 shares | -2% | |
| 36Weak | ANI PHARMACEUTICALS INC | Nikhil Lalwani PRESIDENT & CEO | $383k 5,400 shares | -2% | |
| 18Weak | ANI PHARMACEUTICALS INC | Jeanne Thoma director | $72k 1,000 shares | -4% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $35k 500 shares | -1% | |
| 29Weak | ANI PHARMACEUTICALS INC | Stephen P. Carey SVP & CFO | $207k 2,850 shares | -2% | |
| 13Weak | ANI PHARMACEUTICALS INC | Krista Davis SVP, CHIEF HR OFFICER | $98k 1,000 shares | -2% | |
| 16Weak | ANI PHARMACEUTICALS INC | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | $39k 400 shares | -1% | |
| 56Moderate | ANI PHARMACEUTICALS INC | Antonio R Pera director | $692k 7,292 shares | -24% | |
| 53Moderate | ANI PHARMACEUTICALS INC | Matthew J Leonard director | $229k 2,528 shares | -27% | |
| 41Moderate | ANI PHARMACEUTICALS INC | Krista Davis SVP, CHIEF HR OFFICER | $161k 1,763 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.